Raymond James analyst Andrew Cooper initiates coverage on Natera (NASDAQ:NTRA) with a Market Perform rating.
B of A Securities Maintains Buy on Kiniksa Pharmaceuticals, Lowers Price Target to $34
B of A Securities analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and lowers the price target from $37 to $34.